Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF?, to create a variety of protein therapeutics initially for cancer and autoimmune disorders. The company's two product candidates are wholly owned: STRO-001, an antibody-drug conjugates (ADC) directed against CD74, for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
- ExchangeNASDAQ Stock Market
- SectorPharmaceuticals & Biotechnology
- CountryUnited States